Table 1.

Included trials

Trial identifier	Dates of accrual	Sample size	Cancer therapy
N0528	08/08/2007–11/24/2008	96	(A) Gemcitabine + carboplatin + cediranib vs. (B) gemcitabine + carboplatin
N0426	07/06/2006–01/25/2007	48	Pemetrexed + bevacizumab
N0326	02/10/2005–06/09/2005	25	Sorafenib
N0323	04/30/2004–10/19/2006	52	Temsirolimus
N0222	12/03/2004–02/22/2006	62	(A) Carboplatin + paclitaxel followed by gefitinib vs. (B) gefitinib
N0026	09/05/2001–05/23/2003	150	(A, B, C) Pemetrexed + gemcitabine (administered via different schedules)
N0022	04/30/2001–03/06/2002	58	Vinorelbine
N9921	02/02/2000–02/07/2001	49	Carboplatin + paclitaxel
982453	12/15/1999–03/30/2001	36	Irinotecan + docetaxel
982452	03/08/1998–06/12/2000	99	(A, B) Docetaxel + gemcitabine (administered via different schedules)
972451	06/01/1999–04/06/2004	147	(A) Carboxy‐amino‐imidazole (CAI) vs. (B) placebo